Treatment of endocrine pancreatic tumors

Acta Oncologica

Volumn 44, Issue 4, 2005, Pages 329-338

  Fjällskog, Marie Louise ^a   Janson, Eva Tiensuu ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CHLOROZOTOCIN; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DIAZOXIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; NEUTRALIZING ANTIBODY; OCTREOTATE LU 177; OCTREOTIDE; OCTREOTIDE Y 90; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ARTIFICIAL EMBOLISM; BLOOD TOXICITY; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DOSE RESPONSE; FEVER; FLATULENCE; FLU LIKE SYNDROME; GALLSTONE FORMATION; HUMAN; INCIDENCE; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LUNG SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; PANCREAS ISLET CELL TUMOR; PARTIAL HEPATECTOMY; POLYMYOSITIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SEPSIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROIDITIS; VASCULITIS; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; ENDOCRINE GLAND NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS;

EID: 22544482047     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029941     Document Type: Review

References (96)

1. Wilder RM, Allan FN, Power MH, Robertson HE. Carcinoma of the islands of the pancreas. Hyperinsulinism and hypoglycemia. J Am Med Assoc 1927;89:348-55.
2. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-28.
3. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet 1974;2:1-5.
4. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958;25:374-80.
5. Ganda OP, Weir GC, Soeldner JS, et al. "Somatostatinoma": a somatostatin containing tumor of the endocrine pancreas. N Engl J Med 1977;296:963-7.
6. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986;315:1-5.
7. Imura H. Ectopic hormone syndromes. Clin Endocrinol Metab 1980;9:235-60.
8. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999;10:170-6.
9. Corbetta S, Peracchi M, Cappiello V, et al. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: Identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 2003;88:3117-20.
10. Eriksson B, Arnberg H, Lindgren PG, et al. Neuroendocrine tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103-13.
11. Rindi G, Capella C, Solcia. Cell biology, clinicopathological profile, and classification of gastro-emeropancreatic endocrine tumors. J Mol Med 1998;76:413-20.
12. Eriksson B, Arnberg H, Oberg K, et al. Chromogranins-new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325-9.
13. Schurmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992;16:697-701.
14. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004;43:617-25.
15. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 2004;43:626-36.
16. Welbourn RB, Wood SM, Polak JM, Bloom SR. In: Pancreatic endocrine tumors. Bloom SR, Polak JR, editors. Gut Hormones, 2nd edition. London: Churchill Livingstone; 1981. p. 547-1554.
17. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992;112:1024-31.
18. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-42.
19. Montenegro F, Lawrence GD, Macon W, Pass C. Metastatic glucagonoma: improvement after surgical debulking. Am J Surg 1980;139:424-7.
20. Nagorney DM, Blood SR, Polak JM, Blumgart LH. Resolution of recurrent Verner-Morrison syndrome by resection of metastatic vipoma. Surgery 1983;93:348-53.
21. Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998;22:309-18.
22. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002;132:976-82.
23. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extra-hepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery 2003;133:375-82.
24. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859-66.
25. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet carcinomas of the pancreas; a twenty-year experience. Surgery 1988;104:1011-7.
26. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-85.
27. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002;26:1052-6.
28. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985-90.
29. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-54.
30. Lang H, Schutt HJ, Schmidt H, et al. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas-a single center experience with ten patients. Langenbecks Arch Surg 1999;384:370-7.
31. Fernandez JA, Robles R, Marin C, et al. Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc 2003;5:1832-3.
32. Ackerman NB, Sien WM, Silverman NA. The blood supply of experimental liver metastases. 3. The effects of acute ligation of hepatic artery or portal vein. Surgery 1972;71:636-41.
33. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumor metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988;108:340-4.
34. Carrasco CH, Chuang V, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983;149:79-83.
35. Weiss RB. Streptozotocin: A review of its pharmacology, efficacy and toxicity. Cancer Treat Rep 1982;66:427-38.
36. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-18.
37. Moertel CG, Lavin P, Hahn G. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982;66:1567-9.
38. Altimari A, Badrinath K, Reisel HJ, Printz RA. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 1987;102:1009-17.
39. Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared to streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-94.
40. Moertel CG, Lefkopoulo M, Lipsitz M, Hahn RG, Klaassen D. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
41. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883-90.
42. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-8.
43. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in anaplastic variants of these neoplasma. Cancer 1991;68:227-32.
44. Fjällskog M-L, Granberg D, Welin S, et al. Treatment with cisplatin and etoposid in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
45. Isaac A, Lindenmann J, Virus interference. I. The interferon. By A Isaacs and J Lindenmann, 1957. J Interferon Res 1987;7:429-38.
46. Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 1990;50:3413-5.
47. Grandér D, Öberg K, Lundqvist M-L, Janson ET, Eriksson B, Einhorn S. Interferon-induced enhancement of 2′-5′-oligoadenylat synthetase in mid-gut carcinoid tumors. Lancet 1990;336:337-40.
48. Oberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-33.
49. Eriksson B, Oberg K, Aim G, et al. Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon. Lancet 1986;2:1307-9.
50. Ronnblom LE, Alm GV, Oberg K. Autoimmun phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991;30:537-40.
51. Öberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon-alfa-2b: development of neutralizing antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81:531-5.
52. Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer drugs 1992;3:567-70.
53. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
54. Reichlin S. Somatostatin. Part 1 and 2. N Engl J Med 1983;309:1495-1501 and 1556-63.
55. Chen C, Vincent JD, Clarke IJ. Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends Endocrinol Metab 1994;5:227-33.
56. Buscail L, Delesque N, Èsteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of proliferation by somatostatin analogues: mediation by human somatostatin receptors ssTR1 and ssTR2. Proc Natl Acad Sci USA 1994;91:2315-9.
57. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptors subtypes ssTR2 and ssTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580-4.
58. Sharma K, Patel YC, Srikant CB. Subtype-elective induction of wild-type p53 and apoptosis, but not cell-cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688-96.
59. Teijeiro R, Rios R, Costoya JA. Activation of somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 2002;12:31-8.
60. Reubi JC, Hacki WH, Lamberts SW. Hormone producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987;65:1127-34.
61. Long RG, Barnes AJ, Adrian TE, et al. Suppression of pancreatic endocrine tumor secretion by long-acting somatostatin analogue. Lancet 1979;2:764-7.
62. Arnold R, Trautmann ME, creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic gastroenteropancreatic tumors. Gut 1996;38:430-8.
63. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041-4.
64. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid tumors and malignant islet cell tumors. Cancer 1997;79:830-4.
65. Tiensuu Janson EM, Ahlström H, Andersson T, Oberg K. Octreotide and interferon-alfa: a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992;28:1647-50.
66. Fjällskog M-L, Sundin A, Westlin J-E, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs. Med Oncol 2002;19:35-42.
67. Faiss S, Pape UF, Bohmig M, et al. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy for metastatic neuroendocrine gastroenteropancreatic tumors. The international lanreotide and interferon alfa study. J Clin Oncol 2003;21:2689-96.
68. Krenning E, Kooij P, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionucleide therapy. Digestion 1996;57(Suppl 1):57-61.
69. 1]-octreotide in patients with neuroendocrine tumors- evaluation of therapeutic and toxic effects. Acta Oncol 1999;38:373-7.
70. Anthony L, Woltering W, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-penterotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-32.
71. 90Y-DOTATOC. J Nucl Med 2002;43:610-6.
72. Kwekkeboom D, Bakker W, Kooij PP, et al. 177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0] octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
73. Kwekkeboom D, Bakker B, Kam BL, et al. Treatment of patients with gastroenteropancreatic (GEP) tumors with a novel radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med 2003;30:417-22.
74. Cavallo-Perin P, Bruno A, Ozzello A, et al. Comparison of acute and subacute effects of deflazacort and prednisone on glucose metabolism in man. Eur J Pharmacol 1984;26:357-62.
75. Grant DB, Dunger DB, Burns EC. Long-term treatment with diazoxid in childhood hyperinsulinism. Acta Endocrinol Suppl 1986;279:340-5.
76. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonomas with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 1986;314:1686-9.
77. Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythemas in the glucagonomas syndrome. Clin Endocrinol 2002;57:827-31.
78. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent results cancer res 1996;142:193-207.
79. Yamashiro Y, Yamamoto K, Sato M. Loperamide therapy in a child with vipoma-associated diarrhea. Lancet 1982;1:1413.
80. Ewe K. Opium drops in diarrhea caused by Crohn disease. Dtsch Med Wochenschr 1997;122:174-5.
81. Engelhardt D, Jacob K, Doerr HG. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome. Klin Wochenschr 1989;67:241-7.
82. Verhelst JA, Trainer PJ, Hewlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin endocrinol 1991;35:169-78.
83. Iser G, Pfohl M, Dorr U, Weiss EM, Seif FJ. Ectopic ACTH secretion due to a bronchopulmonary carcinoid localized by somatostatin receptor scintigraphy. Clin Invest 1994;72:887-91.
84. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737 40.
85. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 1994;56:681-8.
86. Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1-5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003;20:59-67.
87. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999;13:647-55.
88. Druker BJ, Tamura S, Buchdunger E, et al. Effects of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
89. Buchdunger E, Cioffi C, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
90. Ferry D, Hammond L, Ransom M, et al. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000;19:abs 5E.
91. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
92. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloic leukaemia. N Engl J Med 2001;344:1031-7.
93. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase receptor inhibitor, in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000;19:abs 686.
94. Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73.
95. Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumors. Targeting the epidermal growth factor receptor gefitinib (ZD1839). Br J Cancer 2003;89:1766-75.
96. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-6.